Patents by Inventor Marjan Huizing
Marjan Huizing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10953026Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: May 20, 2019Date of Patent: March 23, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20200046747Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Marjan Huizing, May C. Malicdan, Nuria Carrillo
-
Publication number: 20190374561Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: May 20, 2019Publication date: December 12, 2019Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Patent number: 10493087Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.Type: GrantFiled: February 23, 2016Date of Patent: December 3, 2019Assignee: The United States of America, as represented by National Institute of HealthInventors: Marjan Huizing, May C. Malicdan, Nuria Carrillo
-
Patent number: 10335426Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: September 12, 2017Date of Patent: July 2, 2019Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20180235988Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.Type: ApplicationFiled: February 23, 2016Publication date: August 23, 2018Applicant: The United States of America, as represented by National Institute of HealthInventors: Marjan Huizing, May C. Malicdan, Nuria Carrillo
-
Publication number: 20180117072Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: September 12, 2017Publication date: May 3, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Patent number: 9341619Abstract: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder.Type: GrantFiled: March 13, 2014Date of Patent: May 17, 2016Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Emory UniversityInventors: Marjan Huizing, William A. Gahl, Nuria Carrillo-Carrasco, Miao He, Xueli Li, Rong Jiang
-
Publication number: 20160025717Abstract: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject, and determining the ratio of T to ST.Type: ApplicationFiled: March 13, 2014Publication date: January 28, 2016Applicants: EMORY UNIVERSITY, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv, Emory UniversityInventors: Marjan Huizing, William A. Gahl, Nuria Carrillo-Carrasco, Miao He, Xueli Li, Rong Jiang
-
Publication number: 20150290229Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: June 29, 2015Publication date: October 15, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Patent number: 9095597Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: March 8, 2013Date of Patent: August 4, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20140271615Abstract: Methods are disclosed for diagnosing a hyposialylation disorder. Methods are also disclosed for determining the effectiveness of a therapeutic agent for treatment of a hyposialylation disorder in a subject. These methods include measuring an amount of monosialylated Thomsen-Friedenreich (ST) antigen and measuring an amount of non-sialylated Thomsen-Friedenreich antigen (T) in a biological sample, such as a serum or plasma sample from the subject and determining the ratio of T to ST. A ratio of T to monosialylated ST of about 0.06 or higher diagnoses the hyposialylation disorder or indicates that the therapeutic agent is not effective for the treatment of the hyposialylation disorder. In other embodiments, a ratio of T to ST less than about 0.06 indicates that the therapeutic agent is effective for the treatment of the hyposialylation disorder, or the subject does not have the hyposialylation disorder.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicants: EMORY UNIVERSITY, THE UNITED STATES OF AMERICA, as represented by the Secretary,Department of Health and Human ServcInventors: Marjan Huizing, William A. Gahl, Nuria Carrillo-Carrasco, Miao He, Xueli Li, Rong Jiang
-
Patent number: 8410063Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: GrantFiled: May 30, 2008Date of Patent: April 2, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
-
Publication number: 20130058998Abstract: A method for treating a disorder characterized by hyposialylation in a subject that includes administering to the subject an effective amount of (i) a composition comprising N-acetylmannosamine, or a derivative thereof, encapsulated within a liposome, or (ii) a composition comprising N-acetylneuraminic acid, or a derivative thereof, encapsulated within a liposome, wherein the liposome comprises 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol.Type: ApplicationFiled: September 6, 2012Publication date: March 7, 2013Inventors: Marjan Huizing, Tal Yardeni, Christopher M. Jay, Nancy Smyth Templeton, William A. Gahl
-
Publication number: 20100249047Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: May 30, 2008Publication date: September 30, 2010Inventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk